Overview

Safety and Efficacy Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients Undergoing Surgery

Status:
Completed
Trial end date:
2004-08-03
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate whether rAHF-PFM is safe and effective in the treatment of hemophilia A patients undergoing surgery.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Baxalta now part of Shire
Baxalta US Inc.
Treatments:
Factor VIII